ImmuPharma PLC
LSE:IMM
Balance Sheet
Balance Sheet Decomposition
ImmuPharma PLC
ImmuPharma PLC
Balance Sheet
ImmuPharma PLC
| Dec-2006 | Dec-2007 | Dec-2008 | Dec-2009 | Dec-2010 | Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash & Cash Equivalents |
6
|
3
|
12
|
23
|
16
|
12
|
9
|
5
|
5
|
1
|
2
|
3
|
5
|
1
|
6
|
2
|
1
|
0
|
0
|
|
| Cash |
0
|
3
|
12
|
23
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash Equivalents |
6
|
0
|
0
|
0
|
16
|
12
|
9
|
5
|
5
|
1
|
2
|
3
|
5
|
1
|
6
|
2
|
1
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
1
|
1
|
1
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
3
|
1
|
0
|
2
|
1
|
1
|
0
|
0
|
0
|
|
| Total Current Assets |
7
|
3
|
13
|
24
|
17
|
13
|
10
|
7
|
6
|
2
|
6
|
4
|
6
|
4
|
7
|
3
|
2
|
1
|
1
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
|
| Intangible Assets |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
1
|
2
|
1
|
1
|
1
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
7
N/A
|
4
-44%
|
13
+227%
|
25
+84%
|
18
-29%
|
14
-19%
|
11
-26%
|
7
-31%
|
7
-2%
|
3
-55%
|
7
+109%
|
5
-25%
|
9
+73%
|
6
-33%
|
11
+88%
|
6
-45%
|
4
-34%
|
3
-32%
|
1
-64%
|
|
| Liabilities | ||||||||||||||||||||
| Accounts Payable |
0
|
0
|
0
|
4
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
0
|
0
|
1
|
1
|
1
|
1
|
|
| Accrued Liabilities |
1
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
1
|
1
|
1
|
6
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
1
|
2
|
2
|
|
| Long-Term Debt |
0
|
0
|
1
|
0
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
1
N/A
|
1
-27%
|
2
+106%
|
7
+204%
|
2
-76%
|
2
+12%
|
2
+18%
|
2
-14%
|
1
-24%
|
2
+11%
|
1
-24%
|
1
+24%
|
1
-28%
|
1
-49%
|
1
+137%
|
2
+26%
|
1
-8%
|
2
+15%
|
2
-9%
|
|
| Equity | ||||||||||||||||||||
| Common Stock |
7
|
7
|
8
|
8
|
8
|
10
|
8
|
10
|
9
|
11
|
14
|
16
|
18
|
23
|
25
|
28
|
29
|
30
|
30
|
|
| Retained Earnings |
5
|
8
|
2
|
3
|
0
|
3
|
7
|
11
|
14
|
17
|
23
|
29
|
36
|
44
|
41
|
50
|
54
|
57
|
59
|
|
| Additional Paid In Capital |
4
|
4
|
5
|
7
|
7
|
7
|
7
|
8
|
10
|
10
|
16
|
19
|
27
|
27
|
27
|
27
|
29
|
29
|
29
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
2
|
0
|
2
|
2
|
2
|
2
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Total Equity |
6
N/A
|
3
-48%
|
11
+269%
|
18
+61%
|
16
-12%
|
13
-22%
|
8
-33%
|
5
-36%
|
6
+6%
|
2
-70%
|
6
+228%
|
4
-36%
|
8
+113%
|
5
-31%
|
10
+83%
|
4
-54%
|
3
-43%
|
1
-58%
|
1
N/A
|
|
| Total Liabilities & Equity |
7
N/A
|
4
-44%
|
13
+227%
|
25
+84%
|
18
-29%
|
14
-19%
|
11
-26%
|
7
-31%
|
7
-2%
|
3
-55%
|
7
+109%
|
5
-25%
|
9
+73%
|
6
-33%
|
11
+88%
|
6
-45%
|
4
-34%
|
3
-32%
|
1
-64%
|
|
| Shares Outstanding | ||||||||||||||||||||
| Common Shares Outstanding |
73
|
73
|
77
|
81
|
82
|
82
|
82
|
82
|
89
|
89
|
125
|
133
|
139
|
167
|
250
|
285
|
333
|
416
|
416
|
|